Abstract:Temozolomide (TMZ), the standard-of-care chemotherapy for glioblastoma, is a DNA alkylating drug. At cytotoxic doses, TMZ Induces high levels of alkylated DNA, including O6 methyl-guanine (O6MG), ultimately triggering cell death. In sub-lethal levels, O6MGs undergo non-Watson-Crick pairing, facilitating mutagenesis and promote acquired resistance. Whether the cytotoxic or mutagenic effects of TMZ predominate is largely determined by the DNA repair enzyme, Methyl-guanine-methyl transferase (MGMT). MGMT restores TMZ-alkylated DNA into its native form. To date, studies of MGMT have largely focused on its expression in large populations of cells. Variation of MGMT expression at a single cell level and pertinence of this variation to acquired TMZ resistance remains poorly understood. In single cells derived from the same patient-derived glioblastoma line, we found that the cell-to-cell variability in MGMT mRNA expression differed by as much as 10-fold. The distribution of single cell MGMT expression approximated that of a normal distribution. Upon treatment with TMZ, the mean expression of MGMT increased by two-fold. Additionally, TMZ treatment increased the standard deviation of the MGMT expression distribution by ten-fold, causing significant “widening” of the range the MGMT expression. Both of these effects were caused by degradation of miR-181d, an MGMT suppressing miRNA. TMZ treatment triggered the activation of ATM- and Rad3- related (ATR) kinase, which in turn activated Polyribonucleotide nucleotidyltransferase 1 (PNPT1), an RNAse that ultimately degradation of miR-181d. Our results suggest that RNA degradation enhanced stochastic variation in MGMT expression, allowing a wider range of MGMT expression from which the optimally fit clone can emerge. This novel form of TMZ resistance can be suppressed by over-expression of miR-181d, suggesting the potential of microRNA delivery as a therapeutic strategy. Accordingly, miR-181d delivery combined with TMZ treatment effectively cured intracranial murine models of patient derived glioblastoma xenografts (PDX) that expressed high levels of MGMT.

Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell Lines

Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma

Metabolic Vulnerabilities of Temozolomide-Resistant Glioblastoma Cells: Implications for Targeted Therapies and Overcoming Chemoresistance

RDNA-01. Microrna DEGRADATION MEDIATED GENETIC HETEROGENEITY AS A NOVEL MECHANISM FOR TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA

Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis

Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide

Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.

Temozolomide resistance in glioblastoma multiforme

Mitochondrial sites of contact with the nucleus aid in chemotherapy evasion of glioblastoma cells

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres

Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics

In search of effective therapies to overcome resistance to Temozolomide in brain tumours